Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hemosiderosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Hemosiderosis. Displaying page 1 of 1.
    EudraCT Number: 2016-003482-25 Sponsor Protocol Number: CICL670F2429 Start Date*: 2018-04-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A single-arm interventional Phase IV, post-authorisation study evaluating the safety of pediatric patients with transfusional hemosiderosis treated with deferasirox crushed film coated tablets
    Medical condition: Transfusional Hemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10019613 Hemosiderosis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003230-22 Sponsor Protocol Number: CICL670AIT07 Start Date*: 2008-11-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent β-thalassemic patients with cardiac MRI ...
    Medical condition: cardiac iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019024 Haemosiderosis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012418-38 Sponsor Protocol Number: CICL670A2302 Start Date*: 2009-12-18
    Sponsor Name:NOVARTIS FARMA
    Full Title: A multi-center, randomized, double-blind, placebocontrolled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload
    Medical condition: myelodysplastic syndromes(low/int-1 risk)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019613 Hemosiderosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FI (Prematurely Ended) DK (Completed) GB (Completed) BE (Completed) GR (Completed) NL (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-023217-61 Sponsor Protocol Number: 10/0174 Start Date*: 2012-01-27
    Sponsor Name:University College London
    Full Title: A phase IV, open-label, partial cross-over partial parallel, randomized, multi-centre study to compare the gastrointestinal tolerability of once daily oral deferasirox, when administered before or ...
    Medical condition: transfusional haemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10019024 Haemosiderosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004322-42 Sponsor Protocol Number: CICL670A2402E1 Start Date*: 2017-08-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis
    Medical condition: Tranfusional hemosiderosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006147-31 Sponsor Protocol Number: GIMEMA MDS 0306 Start Date*: 2007-05-03
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: An open multicenter clinical trial to evaluate the safety, tolerability and efficacy of Deferasirox (ICL670) in patients affected by Myelodysplastic syndrome and transfusional chronic hemosiderosis.
    Medical condition: Low and intermediate I risk (IPSS score) Myelodysplastic syndrome and transfusion-induced hemosiderosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004217-17 Sponsor Protocol Number: CICL670AUS32 Start Date*: 2011-12-09
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food
    Medical condition: transfusional hemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-003953-16 Sponsor Protocol Number: CICL670A2409 Start Date*: 2007-05-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A one-year, open-label, single arm, multi-centre trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload
    Medical condition: Transfusional iron overload
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) DE (Completed) NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000597-31 Sponsor Protocol Number: CICL670A 0109E1 Start Date*: 2008-06-02
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated do...
    Medical condition: Sickle cell disease patients with transfusional hemosiderosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004008-10 Sponsor Protocol Number: CICL670AHU02 Start Date*: 2008-01-08
    Sponsor Name:Novartis Hungária Kft.
    Full Title: Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload
    Medical condition: In- or outpatients with myelodysplasia or beta thalassaemia major, who have chronic iron overload, as a consequence of frequent blood transfusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-003337-32 Sponsor Protocol Number: CICL670A2204 Start Date*: 2007-03-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: ?Estudio Fase II, multicéntrico, abierto y no comparativo para evaluar la eficacia y la seguridad de ICL670 administrado durante 1 año ajustando la dosis en función de los niveles de ferritina en s...
    Medical condition: Pacientes con diagnóstico de sobrecarga de hierro crónica con anemia dependiente de transfusiones distintas a ß-talasemia y drepanocitosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000360-16 Sponsor Protocol Number: P030 Start Date*: 2009-08-06
    Sponsor Name:Medizinische Universität Innsbruck, Innere Medizin I
    Full Title: EFFECTS OF NIFEDIPINE ON IRON HOMEOSTASIS IN PATIENTS SUFFERING FROM IRONOVERLOAD DISEASES - Effekte von Nifedipin auf die Eisenhomeostase bei Patienten mit Eisenüberladungsstörungen
    Medical condition: Hämochromatose ist eine Gruppe genetischer Erkrankungen (Mutationen) denen eine erhöhte Transferrinsättigung und Ferritinspiegel im Blut und Eisenablagerung in Organen, vor allem Leber, Bauchspeich...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057874 Hereditary hemochromatosis LLT
    9.1 10057876 Secondary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000743-33 Sponsor Protocol Number: SPD602-204 Start Date*: 2014-01-16
    Sponsor Name:Shire Development LLC and International Affiliates
    Full Title: A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in β-thalassemia Subjects Admin...
    Medical condition: Patients 18 years of age and older with transfusional iron overload due to β-thalassemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001377-28 Sponsor Protocol Number: 27577 Start Date*: 2008-06-11
    Sponsor Name:Merck Serono International S.A.
    Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061664 Autoimmune disorder LLT
    9.1 10025139 Lupus erythematosus systemic LLT
    9.1 10047888 Wegener's granulomatosis LLT
    9.1 10002817 Antiphospholipid syndrome LLT
    9.1 10040767 Sjogren's syndrome LLT
    9.1 10039073 Rheumatoid arthritis LLT
    9.1 10028245 Multiple sclerosis LLT
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10011401 Crohn's disease LLT
    9.1 10009900 Colitis ulcerative LLT
    9.1 10003827 Autoimmune hepatitis LLT
    9.1 10049046 Autoimmune thyroiditis LLT
    9.1 10003822 Autoimmune haemolytic anaemia NOS LLT
    9.1 10034697 Pernicious anemia LLT
    9.1 10028417 Myasthenia gravis LLT
    9.1 10018620 Goodpasture's syndrome LLT
    9.1 10018766 Guillain Barre syndrome LLT
    9.1 10043554 Thrombocytopenia LLT
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001476-11 Sponsor Protocol Number: AL002-2 Start Date*: 2020-11-12
    Sponsor Name:Alector Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
    Medical condition: Early Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) PL (Ongoing) DE (Ongoing) IT (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA